影像学严重程度分层的全口服短程方案治疗耐多药/利福平耐药结核:中国多中心随机对照非劣效试验
该开放标签、多中心、随机对照非劣效试验纳入259例耐多药/利福平耐药结核患者,按2:1随机接受影像学严重程度分层的全口服短程方案或2019 WHO指南推荐的18个月方案。改良意向治疗人群中,短程组有利治疗结局率为87.1%(148/170),对照组为81.5%(66/81),组间差异5.6个百分点(95%CI -5.7至13.8;非劣效P=0.03);短程组≥3级不良事件发生率显著更低(27.7% vs 43.0%,P<0.01)。
要点
- 影像学分层全口服短程方案治疗耐药结核的有利结局非劣于18个月长程方案。
- 短程组≥3级不良事件发生率显著低于长程方案组(27.7% vs 43.0%)。
- 该方案按影像学严重程度分三层,为中国耐药结核提供更安全短程选择。
核心结论
- 影像学严重程度分层的全口服短程方案在有利治疗结局上非劣于传统18个月长程方案,且安全性更优。
研究设计与样本
- 开放标签、多中心、随机对照非劣效试验,共随机分配259例耐多药/利福平耐药结核患者,短程组173例、对照组86例,随机比2:1。
- 短程组按影像学严重程度评分分为三个亚组,对照组为基于2019 WHO指南的18个月方案。
- 主要疗效终点为停药后6个月内的有利治疗结局,主要安全性终点为研究期间≥3级不良事件。
- 预设非劣效界值为有利结局组间差异<12个百分点。
主要发现
- 改良意向治疗人群中,短程组有利治疗结局率为87.1%(148/170),对照组为81.5%(66/81),组间差异5.6个百分点(95%CI -5.7至13.8;非劣效P=0.03)。
- 符合方案人群中,短程组有利治疗结局率为89.0%(146/164),对照组为83.1%(64/77),组间差异5.9个百分点(95%CI -7.9至11.7;非劣效P=0.02)。
- 短程组≥3级不良事件发生率显著低于对照组(27.7% vs 43.0%,P<0.01)。
关键数值与推荐
- 非劣效界值:有利治疗结局组间差异<12个百分点。
- 改良意向治疗人群有利结局率:短程组87.1%(148/170) vs 对照组81.5%(66/81),差异5.6个百分点(95%CI -5.7至13.8)。
- 符合方案人群有利结局率:短程组89.0%(146/164) vs 对照组83.1%(64/77),差异5.9个百分点(95%CI -7.9至11.7)。
- ≥3级不良事件:短程组27.7% vs 对照组43.0%,P<0.01。
临床怎么用
- 对于耐多药/利福平耐药结核患者,可考虑采用影像学严重程度分层的全口服短程方案替代18个月长程方案。
- 该短程方案在保持疗效非劣的同时显著降低≥3级不良事件,有利于提高治疗安全性和依从性。
- 启动治疗前应依据影像学严重程度评分进行分层,以匹配相应短程方案亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study evaluated the efficacy and safety of a radiographic severity-stratified, all-oral short-course treatment regimen (STR) for multidrug/rifampicin-resistant tuberculosis in China. METHODS: Enrolled participants were randomly divided (2:1) to receive either an all-oral STR or an 18-month regimen based on the 2019 WHO guidelines as the control. The STR group was divided into three subgroups according to radiographic severity scores. The primary efficacy endpoint was a favourable treatment outcome up to 6 months after discontinuation. The primary safety endpoint was grade ≥3 adverse events (AEs) during the study period. A prespecified noninferiority margin of <12 percentage points were used for the between-group difference in favourable outcomes. RESULTS: A total of 259 participants were randomly divided, with 173 and 86 assigned to the STR and control groups, respectively. In the modified intention-to-treat population, the favourable treatment outcome rate was 87.1% (148/170) in the STR group and 81.5% (66/81) in the control group. The between-group difference was 5.6 percentage points (95% CI, -5.7 to 13.8; p 0.03 for noninferiority). In the per-protocol population, the favourable treatment outcome rate was 89.0% (146/164) in the STR group and 83.1% (64/77) in the control group. The between-group difference was 5.9 percentage points (95% CI, -7.9 to 11.7; p 0.02 for noninferiority). Grade ≥3 AEs occurred significantly less often in the STR group than in the control group (27.7% vs. 43.0%, p < 0.01). CONCLUSIONS: The radiographic severity-stratified STR was noninferior to the traditional longer regimen in achieving favourable treatment outcomes and demonstrated better safety.
引用
- Sun WW, Ren F, Yang FP, et al. Efficacy and safety of a radiographic severity-stratified all-oral short treatment regimen for multidrug/rifampicin-resistant tuberculosis in China: an open-label, multicentre, randomised controlled, noninferiority trial. Clin Microbiol Infect. 2026. PMID: 42372949. doi:10.1016/j.cmi.2026.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。